Chugai Pharmaceutical Co Ltd (JP:4519)
:4519
Want to see JP:4519 full AI Analyst Report?
4519 Stock Chart & Stats
¥8349.00
-¥136.00(-1.98%)
At close: 4:00 PM EST
¥8349.00
-¥136.00(-1.98%)
Day’s Range― - ―
52-Week Range¥5,942.00 - ¥10,700.00
Previous CloseN/A
Volume1.90M
Average Volume (3M)2.77M
Market Cap
¥14.54T
Enterprise Value¥12.67T
Total Cash (Recent Filing)¥850.10B
Total Debt (Recent Filing)¥17.51B
Price to Earnings (P/E)30.7
Beta0.79
Next Earnings
Jul 23, 2026EPS Estimate
74.99Next Dividend Ex-DateN/A
Dividend Yield1.17%
Share Statistics
EPS (TTM)70.13
Shares Outstanding1,679,057,600
10 Day Avg. Volume3,088,480
30 Day Avg. Volume2,774,486
Financial Highlights & Ratios
PEG Ratio2.60
Price to Book (P/B)6.70
Price to Sales (P/S)10.78
P/FCF Ratio43.31
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥10,387.50Price Target Upside24.42% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
EPS Forecast (FY)309.2
Revenue Forecast (FY)¥1.38T
Bulls Say, Bears Say
Bulls Say
Very High And Sustainable MarginsExtremely high gross and net margins provide durable cash generation and pricing flexibility. These margins allow Chugai to fund R&D, pay elevated dividends, and absorb pricing pressure on legacy drugs, supporting long-term profitability and strategic reinvestment across product lifecycles.
Conservative, Low‑leverage Balance SheetMinimal debt and strong returns on capital bolster financial resilience through patent cliffs or trial setbacks. Low leverage preserves flexibility to invest in R&D, pursue partnerships or buybacks, and sustain dividends without needing external financing during industry cyclicality.
Strong Cash Generation And Capital EfficiencyHigh operating cash flow and exceptional ROIC indicate efficient capital deployment and self-funded growth. This durable cash generation supports sustained R&D investment, milestone/royalty commercialization, and dividend policy while providing a buffer to execute partnerships and pipeline advancement.
Bears Say
Safety Event And Elevidys Launch DelayA fatal safety event that delays a gene therapy launch creates lasting regulatory scrutiny, potential label restrictions, and reputational impact. Such delays push out revenue realizations, raise development and monitoring costs, and can materially alter commercial timelines for novel therapeutic platforms.
Biosimilar/generic Pressure On Legacy DrugsLoss of exclusivity and biosimilar entry create durable top‑line erosion and pricing pressure on established products. Revenue volatility from legacy brands increases dependence on new launches and royalties, forcing higher R&D efficiency and commercial execution to replace declining cash flows.
Revenue Reliance On Uncertain Royalties/milestonesDependence on milestone and royalty receipts introduces structural earnings volatility because these payments hinge on partner approvals, timing, and external commercialization. This uncertainty complicates multi‑year planning and can produce lumpy cash inflows, raising execution and forecasting risk.
Chugai Pharmaceutical Co News
4519 FAQ
What was Chugai Pharmaceutical Co Ltd’s price range in the past 12 months?
Chugai Pharmaceutical Co Ltd lowest stock price was ¥5942.00 and its highest was ¥10700.00 in the past 12 months.
What is Chugai Pharmaceutical Co Ltd’s market cap?
Chugai Pharmaceutical Co Ltd’s market cap is ¥14.54T.
When is Chugai Pharmaceutical Co Ltd’s upcoming earnings report date?
Chugai Pharmaceutical Co Ltd’s upcoming earnings report date is Jul 23, 2026 which is in 85 days.
How were Chugai Pharmaceutical Co Ltd’s earnings last quarter?
Chugai Pharmaceutical Co Ltd released its earnings results on Apr 24, 2026. The company reported ¥70.13 earnings per share for the quarter, beating the consensus estimate of ¥67.123 by ¥3.007.
Is Chugai Pharmaceutical Co Ltd overvalued?
According to Wall Street analysts Chugai Pharmaceutical Co Ltd’s price is currently Undervalued.
Does Chugai Pharmaceutical Co Ltd pay dividends?
Chugai Pharmaceutical Co Ltd pays a Notavailable dividend of ¥125 which represents an annual dividend yield of 1.17%. See more information on Chugai Pharmaceutical Co Ltd dividends here
What is Chugai Pharmaceutical Co Ltd’s EPS estimate?
Chugai Pharmaceutical Co Ltd’s EPS estimate is 74.99.
How many shares outstanding does Chugai Pharmaceutical Co Ltd have?
Chugai Pharmaceutical Co Ltd has 1,679,057,600 shares outstanding.
What happened to Chugai Pharmaceutical Co Ltd’s price movement after its last earnings report?
Chugai Pharmaceutical Co Ltd reported an EPS of ¥70.13 in its last earnings report, beating expectations of ¥67.123. Following the earnings report the stock price went down -0.907%.
Which hedge fund is a major shareholder of Chugai Pharmaceutical Co Ltd?
Currently, no hedge funds are holding shares in JP:4519
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Chugai Pharmaceutical Co Ltd
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda; osteoporosis, including Actemra, Edirol, and Bonviva; renal diseases consist of Mircera and Oxarol; and neurology/other diseases comprise Hemlibra, CellCept, and Enspryng. It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.
4519 Company Deck
4519 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a strongly positive financial and operational picture: record FY2025 revenue, operating profit and margin, robust FY2026 guidance, significant clinical and pipeline progress (notably NXT007, giredestrant, Enspryng, orforglipron), and disciplined cost control. Key risks were acknowledged — a serious safety event delaying Elevidys launch, biosimilar and generic pressure on legacy products (Actemra, Avastin), several project discontinuations, and some uncertainty around royalty/milestone timing and cash reduction after special dividends. On balance the call emphasized sustained growth, high profitability and a focused R&D strategy while noting manageable but material risks that warrant monitoring.View all JP:4519 earnings summaries4519 Stock 12 Month Forecast
Average Price Target
¥10,387.50
▲(24.42% Upside)
Technical Analysis
Astellas Pharma
―
Daiichi Sankyo Company
―
Eisai Co
―
ONO Pharmaceutical Co
―
Takeda Pharmaceutical Co
―
Options Prices
Currently, No data available
---